Previfenon® as Chemoprophylaxis of COVID-19 in Health Workers
Status:
Not yet recruiting
Trial end date:
2021-10-30
Target enrollment:
Participant gender:
Summary
The purpose of this clinical trial is to determine the efficacy of Previfenon® (EGCG) to
prevent COVID-19, enhance systemic immunity, and decrease the frequency and intensity of
selected symptoms when used as pre-exposure chemoprophylaxis to SARS-CoV-2.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
MELISA Institute Genomics & Proteomics Research SpA